Ovarian Cancer is a tumour that arises from the ovaries or areas of peritoneum or fallopian tube. Ovarian cancer can be symptomized by pain or swelling in the abdomen, gastrointestinal problems such as constipation and gas, pain in the pelvis, and vaginal bleeding. There are several risk factors for occurrence of ovarian cancer such as breast cancer, uterine cancer or colon cancer, endometriosis, have never given birth, having genetic mutation in BRCA1 or BRCA2 gene and patients associated with lynch syndrome. Morphotek, Inc. is in the process of developing farletuzumab as a folate receptor 1 antagonist for the treatment of ovarian cancer. AstraZeneca plc is in the process of developing OLAPARIB as a poly(ADP-ribose) polymerase inhibitor for the treatment of ovarian cancer. Some of the companies having the pipeline of ovarian cancer include Myriad Genetic Laboratories, Inc., Tesaro, Inc., Adaptimmune Therapeutics plc, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.